DROGAS ATUAIS E NOVAS ABORDAGENS TERAPÊUTICAS PARA O TRATAMENTO DA LEISHMANIOSE
DOI:
https://doi.org/10.18554/acbiobras.v2i1.8655Keywords:
Treatment of Leishmaniasis, therapeutic alternatives, metallic complexesAbstract
A leishmaniose é endêmica em 98 países e 5 continentes e aproximadamente 1,3 milhões de novos casos ocorrem anualmente. Neste trabalho estão descritas as principais terapias utilizadas para o tratamento das diversas manifestações clínicas da leishmaniose. Considerando que as drogas anti-Leishmania atualmente disponíveis apresentam vários problemas como graves efeitos colaterais e possibilidade de resistência parasitária ao medicamento, dentre outros, existe uma constante busca pelo desenvolvimento de novas terapias para essa doença. Além das moléculas comumente utilizadas no tratamento da leishmaniose, alternativas terapêuticas promissoras como os complexos metálicos foram destacadas.
References
(1) Lainson, R.; Shaw, J. Evolution, classification and geographical distribution. In: Peters, W.; Killick-Kendrick, R. eds. The leishmaniasis in Biology and Medicine, Biology and Epidemiology. London: Academic Press. 1987, 1120 p.
(2) Anversa, L.; Tiburcio, M. G. S.; Richini-Pereira, V. B.; Ramirez, L. E. 2018. Human leishmaniasis in Brazil: a general review. Revista da Asssociação Médica Brasileira,64(3): 281-289.
(3) Von Stebut, E. 2015. Leishmaniasis. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 13: 191-201.
(4) Sunyoto, T.; Boelaert, M.; Meheus, F. 2019. Understanding the economic impact of leishmaniasis on households in endemic countries: a systematic review. Expert Review of Anti-infective Therapy, 17: 57-69.
(5) Mcgwire, B. S.; Satoskar, A. R. 2014. Leishmaniasis: clinical syndromes and treatment. International Journal of Medicine, 107: 7-14.
(6) Bi, K.; Chen, Y.; Zhao, S.; Kuang, Y.; Wu, C. H. J. 2018. Current visceral leishmaniasis research: a research review to inspire future study. BioMed Research International, 2018: 1-13.
(7) Mosimann, V.; Neumayr, A.; Paris, D. H.; Blum, J. 2018. Liposomal amphotericin B treatment of Old World cutaneous and mucosal leishmaniasis: A literature review. Acta Tropica, 182: 246-250.
(8) Pace, D. Leishmaniasis. 2014. Journal of infection, 69: 510-518.
(9) Aagaard-Hansen, J.; Nombela, N.; Alvar, J. 2010. Population movement: a key factor in the epidemiology of neglected tropical diseases. Tropical Medicine & International Health, 15(11): 1281-1218.
(10) Argaw, D.; Mulugeta, A.; Herreo, M.; Nombela, N.; Teklu, T.; Tefera, T.; Zewdu, B.; Alvar, J.; Bern, C. 2013. Risk factors for visceral leishmaniasis among residents and migrants in Kaft a-Humera, Ethiopia. PLOS Neglected Tropical Diseases, 7(11): 1-9.
(11) Lindoso, J. A. L.; Lindoso, A. A. B. P. 2009. Neglected tropical diseases in Brazil. Revista do Instituto de Medicina Tropical de São Paulo, 51(5): 247-253.
(12) Sarteriale, A.; Bessoff, K.; Sarkar, I. N.; Huston, C. D. 2014. Drug repurposing: mining protozoan proteomes for targets of known bioactive compounds. The Journal of American Medical Informatics Association, 21: 238-244.
(13) Vias, S. J.; Stolk, W. A.; Rutte, E. A.; Hontelez, J. A. C.; Bakker, R.; Blok, D. J.; Cai, R.; Houweling, T. A. J.; Kulik, M. C.; Lenk, E. J.; Luyendijk, M.; Matthijsse, S. M.; Redecop, W. K.; Wagenaar, I.; Jacobson, J.; Nagelkerke, N. J. D.; Richardus, J. H. 2016. Concerted efforts to control or eliminate neglected tropical diseases: how much health will be gained? Plos Neglected Tropical Diseases, 10(2).
(14) Rama, M.; Kumar, N. V. A.; Balaji, S. 2015. A comprehensive review of patented antileishmanial agents. Pharmaceutical Patent Analyst, 4(1): 37-56.
(15) Vianna, G. 1912. Comunicação à Sociedade Brasileira de Dermatologia. Arquivo Brasileiro de Medicina, 2: 426.
(16) Di Cristina, G; Caronia, G. 1915. “Sulla terapia della leishmaniosis interna. Pathologica, 7: 82-83.
(17) Cole, A.C.E. 1944. Kala-azar in east Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 37: 409-435.
(18) Rath, S; Trivelin, L. A; Imbrunito, T. R; Tomazela, D. M; de Jesus, M. N; Marzal, P. C; Junior, H. F. A; Tempene, A.G. 2003. Antimoniais empregados no tratamento da leishmaniose: estado da arte. Química Nova, 6(4): 550-555.
(19) Lima, E. B.; Motta, J. O. C.; Porto, C.; Sampaio, R. N. R. 2007. Tratamento da leishaniose tegumentar americana. Anais Brasileiros de Dermatologia, 82(2): 111-124.
(20) Balaña-Fource, R.; Reguera, R. M.; Cubría, J. C.; Ordóñez, D. 1998. The pharmacology of leishmaniasis. General Pharmacology, 30(4): 435-443.
(21) Turrens, J. F. 2004. Oxidative stress and antioxidant defenses: a target for the treatment of diseases caused by parasitic protozoa. Molecular Aspects of Medicine, 25: 211-220.
(22) Haldar, A. K.; Sen, P.; Roy, S. 2011. Use of antimony in the treatment of leishmaniasis: current status and future directions. Molecular Biology International, 2011: 1-23.
(23) Sundar, S.; Chakravarty, J. 2015. An update oh pharmacotherapy for leishmaniasis. Expert Opinion on Pharmacotherapy, 16(2): 237-252.
(24) Handler, M. Z.;Patel, P. A.; Kapila, R.; Al-Qubati, Y.; Schwartz, R. A. 2015. Cutaneous and mucocutaneous leishmaniasis: differential diagnosis, diagnosis, histopathology and management. Journal of the American Academy of Dermatology, 73(6): 911-926.
(25) Herwaldt, B. L.; Berman, J. D. 1992. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. American Journal of Tropical Medicine & Hygiene, 46(3): 296-306.
(26) Abramowicz, M. 1993. Drugs for parasitic infections. The Medical letter on drugs and therapeutics, 1993(33): 111-122.
(27) Prata, A. Treatment of kala-azar with amphotericin B. 1963. Transactions of the Royal Society of Tropical Medicine and Hygiene, 57(4): 266-268.
(28) Andrews, K. T.; Fisher, G.; Skinner-Adams, T. S. Drug repurposing and human parasitic protozoan diseases. 2014. International Journal for Parasitology: Drug and Drug Resistance, 4: 95-111.
(29) Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Manual de Vigilância da Leishmaniose Tegumentar Americana/Ministério da Saúde. Brasília: Editora do Ministério da Saúde, 2013.
(30) Solomon, M. P. F.; Barzilai, A.; Schwartz, E. 2013. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers. Journal of the American Academy of Dermatology, 68(2): 284-289.
(31) Motta, J. O.; Sampaio, R. N. 2012. A pilot study comparing low-dose liposomal amphotericin B with N-methyl glucamine for the treatment of American cutaneous leishmaniasis. Journal of the European Academy of Dermatology and Venereology, 26: 331-335.
(32) Nagle, A. S.; Khare, S..; Kumar, A. B.; Supek, F.; Buchynskyy.; Mathison, C. J.; Chennamaneni, N. K.; Pendem, N.; Buckner, F. S.; Gelb, M. H.; Molteni, V. 2014. Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. Chemical Reviews, 26(114): 11305-11347.
(33) Lourie, E. M.; Orke, W. 1939. Studies in chemotherapy. XXI. The trypanocidal action of Certain aromatic diamidines. Annals of Tropical Medicine Parasitology, 33: 289-304.
(34) Lourie, E. M. 1942.Treatment of sleeping sickness in Sierra Leone. Annals of Tropical Medicine Parasitology, 36: 113-131.
(35) Hazarika, A. N. 1949. Treatment of kala-azar with pentamidine isothionate; a study of 55 cases. The Indian Medical Gazette, 84(4): 140-145.
(36) Martínez, A.; Carreon, T.; Iniguez, E.; Anzelotti, A.; Sánchez, A.; Tyan, M.; Sattler, A.; Herrera, L.; Maldonado, R. A.; Sáchez-Delgado, R. A. 2012. Searching for new chemotherapies for tropical diseases: Ruthenium – Clotrimazole complexes display high in vitro activity against Leishmania major and Trypanosome cruzi and low toxicity toward normal mammalian cells. Journal of Medicinal Chemistry, 55:3867-3877.
(37) de Paula, C. D.; Sampaio, J. H.; Cardoso, D. R.; Sampaio, R. N. 2003. A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20mgSbV/day for 20 days to treat cutaneous leishmaniasis. Revista da Sociedade Brasileira de Medicina Tropical, 36(3): 365-371.
(38) Mitropoulos, P.; Konidas, P.; Durkin-Konidas, M. 2010. New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment. Journal of the American Academy of Dermatology, 63(2): 309-322.
(39) Roussel, M; Nacher, M; Fremont, G; Roturneau, B; Clyti, E; Sainte-Marie, D; Carme, B; Pradinaud, R; Couppie, P. 2006. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Annals of Tropical Medicine and Public Health, 100(4): 307-314.
(40) Hellier, I.; Dereure, O.; Tournillac, I.; Pratlong, F.; Guillot, B.; Dedet, J. P.; Guilhou, J. J. 2000. Treatment of Old World cutaneous leishmaniasis by pentamidine isethionate. An open study of 11 patients. Dermatology, 200(2): 120-12.
(41) Croft, S. L.; Snowdon, D.; Yardley, V. 1996. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and
Trypanosoma brucei. Journal of Antimicrobial Chemotherapy, 38(6): 1041-1047. (42) Singh, N.; Kumar, M.: Singh, R. K. 2012. Leishmaniasis: current status of available drugs and new potential srug targets. Asian Pacific Journal of Tropical
Medicine, 5(6): 485-497.
(43) Machado, P. R.; Ampuero, J.; Guimarães, L. H.; Villasboas, L.; Rocha, A. T.; Schriefer, A.; Souza, R. S.; Talhari, A.; Penna, G.; Carvalho, E. M. 2010. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLOS Neglected Tropical Diseases, 21(4): 1-6.
(44) Monge-Maillo, B.; López-Vélez, R. 2013. Therapeutic options for Old World cutaneous Leishmaniasis and New World Cutaneous and Mucocutaneous Leishmaniasis. Drugs, 73: 1889-1920.
(45) Soto, J.; Rea, J.; Valderrama, M.; Toledo, J.; Valda, L.; Ardiles, J.; Berman, J. 2009. Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia. American Journal of Tropical Medicine & Hygiene, 81:387-379.
(46) Correia, D.; Macedo, V. O.; Carvalho, E. M.; Barral, A.; Magalhaes, A. V.; de Abreu, M. V.; Orge, M. L., Marsden, P. 1996. Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulphate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis. Revista da Socidade Brasileira de Medicina Tropical, 29(5): 447-453.
(47) Burrows, J. N.; Elliott, R. L.; Kaneko, T.; Mowbray C. E. Waterson, D. 2014. The role of modern drug discovery in the fight against neglected and tropical diseases. Medicinal Chemistry Communications, 5: 688-700.
(48) Falci, D. R.; Pasqualotto, A. C. 2015. Anfotericina B: uma revisão sobre suas diferentes formulaões, efeitos adversos e toxicidade. Clinical & Biomedical Research, 35(2): 65-82.
(49) Dorlo, T. P. C.; Kager, P. A. 2008. Pentamidine dosage: a base/salt confusion. PLOS Neglected Tropical Diseases, 2(5): 1- 3.
(50) Rosenberg, B.; Vancamp, L.; Krigas, T. 1965. Inhibition of cell division in Escherichia Coli by electrolysis products from a platinum electrode. Nature, 205:
698-699.
(51) Komeda, S.; Casini, A. 2012. Next-Generation Anticancer Metallodrugs. Current Topics in Medicinal Chemistry, 12(3): 219-235.
(52) Pereira, F. C; Lima, B. A. V; de Lima, A. P; Pires, W. C; Monteiro, T; Magalhaes, L. F; Costa, W; Graminha, A. E; Batista, A. A, Ellena, J; SilveiraLacerda, E. P. 2015. Cis-[RuCl(BzCN)(N-N)(P-P)]PF6 complexes: Synthesis and in vitro antitumor activity: (BzCN=benzonitrile; N-N=2,2'-bipyridine; 1,10- phenanthroline; P-P=1,4-bis(diphenylphosphino) butane, 1,2-bis(diphenylphosphino)ethane, or 1,1'-(diphenylphosphino)ferrocene). Journal of Inorganic Biochemistry, 149: 91-101.
(53) Bates, J. N; Baker, M. T; Guerra, R; HÁRRISON, D. G. 1991. Nitric oxide generation from nitroprusside by vascular tissue: Evidence that reduction of the nitroprusside anion and cyanide loss are required. Biochemical Pharmacology, 42(1): 157-165.
(54) Sánchez-Delgado, R. A.; Lazardi, K.; Rincón, L.; Urbina, J. A. 1993. Toward a novel metal-based chemotherapy against tropical diseases. 1. Enhancement of the efficacy of clotrimazole against Trypanosoma cruzi by complexation to ruthenium in RuCl2(clotrimazole)2. Journal of Medicinal Chemistry, 36(14): 2041-2043.
(55) Martinez Garcia, P.; Guasch, J.; Llaurado, F. 1950. First cases of infantile kalaazar treated in Spain with diamidines (stilbamidine and pentamidine). Revista Española Pediatría, 6(3): 319-346.
(56) Barbosa, M. I; Correa, R. S; DE Oliveira, K. M; Rodrigues, C; Ellena, J; Nascimento, O. R; Rocha, V. P; Nonato, F. R; Macedo, T. S; Barbosa-Filjo, J. M; Soares, M.B; Batista, A. A. 2014. Antiparasitic activities of novel ruthenium/lapachol complexes. Journal of Inorganic Biochemistry, 136: 33-39.
(57) Borst, P. 1977. Metabolism and chemotherapy of African trypanosomes, Transactions of the Royal Society of Tropical Medicine and Hygiene, 71: 3-4.
(58) Farrell, N. P; Williamson, J, Mclaren, D. J. M. 1984. Trypanocidal and antitumour activity of platinum-metal and platinum-metal-drug dual-function complexes. Biochemical Pharmacology, 33: 961-971.
(59) Farrell, N. P. Transition metal complexes as drugs and chemotherapeutic
agents. Dordrecht: Kluwer Academic Publishers. 1989.
(60) Navarro, M.; Gabbiani, C.; Messori, L.; Gambino, D.2010. Metal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives. Drug Discovery Today, 15: 1070-1078.
(61) Gambino, D.; Otero, L. 2012. Perspectives on what ruthenium-based compounds could offer in the development of potential antiparasitic drugs. Inorganica Chimica Acta, 393: 103-114.
(62) Bratsos, I.; Jedner, S.; Gianferrara, T.; Alessio, E. 2007. Ruthenium anticancer compounds: challenges and expectations. International Journal of Chemistry, 61:692-697.
(63) Hartinger, C. G.; Jakupec, M. A.; Zorbas-Seifried, S.; Groessi, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P. J.; Keppler, B. K. 2008. KP1019, a new redoxactive anticancer agent--preclinical development and results of a clinical phase I study in tumor patients. Chemistry & Biodiversity, 5(10): 2140-2155.
(64) Sánchez-Delgado, R. A.; Anzellotti, A. 2004. Metal complexes as chemotherapeutic agents against tropical diseases: Trypanosomiasis, Malaria and Leishmaniasis. Mini-Reviews in Medicinal Chemistry, 4(1): 23-30.
(65) Sánchez-Delgado, R. A.; Navarro, M.; Lazardi, K.; Atencio, R.; Capparelli, M.; Vargas, F.; Urbina, J. A.; Bouillez, A.; Noels, A. F.; Masi, D. 1998. Toward a novel metal based chemotherapy against tropical diseases 4. Synthesis and characterization of new metal-clotrimazole complexes and evaluation of their activity against Trypanosoma cruzi. Inorganica Chimica Acta, 275-276.
(66) Navarro, M.; Lehmann, T. E.; Cisneros-Farjado, E. J.; Fuentes, A.; SánchezDelgado, R. A.; Silva, P.; Urbina, J. A. 2000. Toward a novel metal based
chemotherapy against tropical diseases. Synthesis and characterization of new
Ru(II) and Ru(III) clotrimazole and ketoconazole complexes and evaluation of their activity against Trypanosoma Cruzi. Polyhedron, 19: 2319-2325.
(67) Costa, M. S.; Gonçalves, Y. G.; Nunes, D. C. O.; Napolitano, D. R.; Maia, P. I. S.; Rodrigues, R. S.; Rodrigues, V. M.; Von Poelhsitz, G.; Yoneyama, K. A. G. 2017. Anti- Leishmania activity of new ruthenium(II) complexes: Effect on parasite-host interaction. Journal of Inorganic Biochemistry, 175: 225-231.
(68) Frandzloch, M.; Arriaga, J. M. M.; Sánchez-Moreno, M.; Wojtczak, A.; Jezierska, J.; Sitkowski, J.; Wisniewska, J.; Salas, J.M.; Lakomska, I. 2017. Strategies of overcoming tropical disease by Ruthenium Complexes with purine analog: application against leishmania spp and Trypanosoma cruzi. Journal of Inorganic Biochemistry, 176: 144-155.
(69) Do Nascimento, N. R. F.; De Aguiar, F. L. N. Santos, C.F., Costa, A. M. L., Hardoim, D. J., Calabrese, K. S., Almeida-Souza, F., De Sousa, E. H. S., Lopes, L. G. F., Teixeira, M. J., Pereira, V.S., Brilhante, R. S. N., Rocha, M. F. G. 2019. In vitro and in vivo leishmanicidal activity of a ruthenium nitrosyl complex against Leishmania (Viannia) braziliensis. Acta Tropica, 192: 61 – 65.
(70) Costa, M.S., Gonçalves, Y.G., Teixeira, S.C.,Nunes, D. C. O., Lopes, D. S., Da Silva, C. V., Da Silva, M. S., Borges, B. C.,Silva, M. J. B., Rodrigues, R. S., Rodrigues, V. M., Von Poelhsitz, G., Yoneyama, K,A. G. 2019. Increased ROS generation causes apoptosis-like death: Mechanistic insights into the antiLeishmania activity of a potent ruthenium(II) complex. Journal of Inorganic Biochemistry,195: 1-12.
Revistas UFTM